August 24, 2015
Janssen Pharmaceutical K.K. said on August 20 that the company and the National Center of Neurology and Psychiatry (NCNP) will collaborate for the development of biomarkers that can identify patients who can benefit from its Alzheimer’s disease (AD) treatment Reminyl...read more